Loading
Across seven tumour types including endometrial, cervical and ovarian cancers, trastuzumab deruxtecan shrank tumours in about 37 percent of patients overall and 61 percent of those with the highest HER2 expression, leading to a tumour-agnostic approval.
Phase 2 study of 267 patients with previously treated HER2-expressing (immunohistochemistry 3+ or 2+) advanced solid tumours in seven cohorts (endometrial, cervical, ovarian, bladder, biliary, pancreatic and other) treated with trastuzumab deruxtecan 5.4 mg/kg.
Objective response was 37.1 percent overall and 61.3 percent in immunohistochemistry 3+ tumours, with median duration of response 11.3 and 22.1 months respectively; endometrial (57.5 percent) and cervical (50.0 percent) cohorts responded best. Interstitial lung disease occurred in 10.5 percent.
HER2 immunohistochemistry is now worth doing in advanced gynaecological and other cancers, since trastuzumab deruxtecan is approved for HER2 3+ solid tumours after prior therapy.
Shares DESTINY-PanTumor02, Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab deruxtecan.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab deruxtecan, Trastuzumab, Journal of Clinical Oncology.
Shares Uterine carcinosarcoma, Journal of Clinical Oncology.
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab deruxtecan, Trastuzumab.